@xconomy.com 1 month ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com 4 months ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 5 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 6 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 1 year ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 1 year ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com 1 year ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@xconomy.com 1 year ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 1 year ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com 1 year ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 1 year ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 1 year ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More